CFO Cecilia Edström appointed deputy CEO
The Board of Directors has appointed Chief Financial Officer (CFO) Cecilia Edström deputy CEO of Bactiguard, in addition to her current responsibilities.
”Cecilia Edström was recruited to Bactiguard ahead of the IPO in 2014 and has had several roles in the company since then. This means that she has acquired a broad and deep knowledge of Bactiguard's business.
Cecilia has earlier been a member of the executive management teams of both Scania and TeliaSonera and in her current role as CFO, she has become an important partner to me in the management team of Bactiguard. She takes great responsibility for strategy and business development and it is therefore a natural step to appoint her deputy CEO of the company. The Board is very positive about the appointment, which contributes to increased seniority and stability in the management and we are all pleased that she accepted the role,” says Christian Kinch, CEO.
Cecilia Edström was born in 1966 and holds a degree in business economics from the Stockholm School of Economics. She started her career in corporate finance at Skandinaviska Enskilda Banken and was thereafter recruited to Scania ahead of the company's IPO. At Scania, she was responsible for investor and corporate relations, business development, strategy and communication for a total of thirteen years in the company. In connection with Volkswagen's acquisition, she left Scania and became Head of Group Communications at TeliaSonera.
Cecilia Edström owns 243,264 B shares in Bactiguard.
For further information, please contact:
Cecilia Edström, CFO, cell phone: +46 72 226 23 28
About Bactiguard
Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission we develop and supply infection protection solutions which reduce the risk of healthcare associated infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.
The Bactiguard technology prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Through our licence partner BD, urinary catheters with Bactiguard’s coating are market leading in the USA and Japan. Bactiguard’s own product portfolio of urinary catheters, endotracheal tubes and central venous catheters prevent some of the most common infections, which appear in the urinary tract, the blood stream and the respiratory tract.
Bactiguard is in a strong expansion phase in the European markets, China, India and the Middle East as well by establishing license agreements in new therapeutic areas. The company has about 70 employees around the world. Its headquarters and one of two production facilities are located in Stockholm, the other one in Malaysia. Bactiguard is listed on Nasdaq Stockholm.
Read more about how Bactiguard saves lives on www.bactiguard.com
Tags:
